Loading organizations...
Based in Shreveport-Bossier, Louisiana, Glaive Medical Optics is an ophthalmology company developing innovative image-shifting intraocular lens technology to restore vision in patients suffering from blinding macular diseases like macular degeneration. The enterprise was founded by ophthalmologist Doctor Christopher L Shelby, developer of the iExaminer, and Doctor Wayne Harvey Woods Jr, a former Massachusetts Institute of Technology quantum computing researcher, alongside CEO Eric Bernabei. To create these transformative implants, the firm combines specialized expertise in optics, engineering, and materials science, enabling patients to see what was previously impossible. On July 9, 2025, Doctor Shelby appeared on the On The Cusp podcast to discuss the company's proprietary lens technology and its growing patent portfolio. Currently, the medical device manufacturer is actively seeking between $1 million and $5 million in seed investment to further commercialize its innovations.
Glaive Medical Optics has raised $400K across 1 funding round.
Key people at Glaive Medical Optics.
Glaive Medical Optics has raised $400K in total across 1 funding round.
Glaive Medical Optics has raised $400K across 1 funding round. Most recently, it raised $400K Seed in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $400K Seed | — | CE Innovation Capital, KittyHawk Ventures, MUFG Innovation Partners | Announced |
Glaive Medical Optics has raised $400K in total across 1 funding round.
Glaive Medical Optics's investors include CE Innovation Capital, KittyHawk Ventures, MUFG Innovation Partners.
Key people at Glaive Medical Optics.
Glaive Medical Optics is a technology company specializing in ophthalmology, focused on developing innovative intraocular lens technology to restore vision for patients suffering from blinding macular diseases, particularly end-stage macular degeneration. Their flagship product, the GlaiveOptix Lens, integrates proprietary nanotechnology into a miniature implantable device designed to shift images and enable patients with central vision loss to see more clearly. This breakthrough offers a transformative solution for patients who have exhausted other treatments, providing new hope for regaining sight and independence[1][2][3].
The company serves patients with severe macular diseases, ophthalmologists, and the broader medical community by addressing a critical unmet need in vision restoration. Glaive Medical Optics is gaining momentum through its pioneering technology and patents, positioning itself as a leader in the intersection of medical innovation and vision care[1][3].
Glaive Medical Optics was co-founded by Dr. Christopher Shelby, a respected ophthalmologist with a history of innovation in ophthalmic technology, including the development of the iExaminer, a retinal camera that leverages smartphone technology. Dr. Shelby, together with his brother-in-law Wayne Woods, developed several innovative patents that led to the creation of the company and its groundbreaking image-shifting intraocular lens. Their work emerged from a clinical need to provide solutions for patients with macular scarring and central vision loss, conditions for which existing treatments are ineffective at advanced stages[1][3].
The company is based in Shreveport, Louisiana, and has evolved by combining clinical expertise, advanced materials science, and fabrication technology, with contributions from experts like Dr. Melville, a materials scientist with experience at Onsemi and MIT Lincoln Labs. Early traction includes the development of patented technology and recognition within the ophthalmology and medical device communities[1][3][4].
Glaive Medical Optics is riding the wave of advanced medical device innovation, particularly in ophthalmology, where there is a significant unmet need for treatments addressing irreversible vision loss from macular diseases. The timing is critical as the global population ages and the prevalence of macular degeneration rises, increasing demand for effective vision restoration technologies. Market forces such as advances in nanotechnology, miniaturization of medical implants, and digital imaging converge to support Glaive’s approach.
By pioneering implantable lenses that combine therapeutic and diagnostic functions, Glaive influences the broader ecosystem by pushing the boundaries of what intraocular devices can achieve, potentially setting new standards for vision care and patient outcomes[1][2][3].
Looking ahead, Glaive Medical Optics is poised to advance clinical trials, regulatory approvals, and commercialization of its innovative lens technology. Trends shaping their journey include the growing emphasis on personalized medicine, integration of digital health tools, and increasing investment in ophthalmic innovation. As the company scales, it may expand its technology platform to address other vision impairments and collaborate with healthcare providers to integrate its diagnostic capabilities.
Glaive’s influence is likely to grow as it demonstrates the viability of combining therapeutic implants with imaging technology, potentially transforming treatment paradigms for macular diseases and inspiring further innovation in medical optics. Their mission to restore sight to the blind aligns with broader healthcare goals of improving quality of life through cutting-edge science[1][3].
